A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

Shares of Amgen (NASDAQ: AMGN) recently ticked lower despite a very positive-sounding press release regarding its weight ...

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed ...

Amgen (AMGN) announced positive data at 52 weeks in a double-blind, dose-ranging Phase 2 study with MariTide – maridebart ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

Analyst Mohit Bansal of Wells Fargo maintained a Hold rating on Amgen (AMGN – Research Report), retaining the price target of $335.00.Don't ...

Shares in Amgen fell on Tuesday after they announced the results of a trial for their weight loss drug MariTide.

Terence Flynn, an analyst from Morgan Stanley, maintained the Hold rating on Amgen (AMGN – Research Report). The associated price target ...

That increased convenience will have to be accompanied by weight loss that is at least as effective as its rivals, and Amgen ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...